Literature DB >> 8786198

72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study.

M De Nictolis1, S Garbisa, G Lucarini, G Goteri, L Masiero, A Ciavattini, G G Garzetti, W G Stetler-Stevenson, G Fabris, G Biagini, J Prat.   

Abstract

The immunohistochemical expression of 72-kDa type IV collagenase [matrix-metalloproteinase (MMP)-21], basement membrane component type IV collagen and proliferation-related antigen Ki 67 were investigated in 43 benign, borderline, and malignant serous tumors of the ovary. The results were compared with the histotypes of ovarian serous tumors and with their clinical behavior. Serum evaluation of MMP-2 was performed in 14 patients with cystadenocarcinoma and the data compared with that of a control group. The basement membrane (BM) was continuous in benign cystadenomas and in some borderline tumors, whereas it was discontinuous or absent in other borderline tumors, in borderline tumors with microinvasion, and cystadenocarcinomas. The percentage of MMP-2- and Ki 67-expressing cells increased from cystadenomas to borderline tumors, being the highest in malignant tumors; a frequent basal disposition of the MMP-2 cytoplasmic granules also was observed in cystadenocarcinomas. Statistical analysis demonstrated that MMP-2 expression was inversely related to BM integrity. Serum MMP-2 values did not differ from that of the control group. Cox regression analysis showed that tumor stage and grade were significant prognostic factors, whereas MMP-2 and Ki 67 immunohistochemical expression added no further significant information to the prognosis. The investigators conclude that the correlation between increasing MMP-2 expression and BM alteration gives support to the hypothesis of a direct role of the metalloproteinase in the process of destructive stromal invasion. MMP-2, type IV collagen, and Ki 67 immunodetection varied according to the histologic classification of ovarian serous tumors. However, neither these factors nor the serum evaluation of MMP-2 appear useful as prognostic predictors in this series.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786198     DOI: 10.1097/00004347-199604000-00003

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  6 in total

1.  High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma.

Authors:  B Davidson; I Goldberg; W H Gotlieb; J Kopolovic; G Ben-Baruch; J M Nesland; A Berner; M Bryne; R Reich
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

2.  Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas.

Authors:  N Johansson; M Vaalamo; S Grénman; S Hietanen; P Klemi; U Saarialho-Kere; V M Kähäri
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

3.  Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma.

Authors:  Brian P Adley; Kara J Gleason; Ximing J Yang; M Sharon Stack
Journal:  Gynecol Oncol       Date:  2008-10-30       Impact factor: 5.482

4.  The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.

Authors:  A Paju; T Sorsa; T Tervahartiala; E Koivunen; C Haglund; A Leminen; T Wahlström; T Salo; U H Stenman
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

5.  Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.

Authors:  M N Holten-Andersen; G Murphy; H J Nielsen; A N Pedersen; I J Christensen; G Høyer-Hansen; N Brünner; R W Stephens
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

Review 6.  Extracellular matrix as target for antitumor therapy.

Authors:  Revekka Harisi; Andras Jeney
Journal:  Onco Targets Ther       Date:  2015-06-09       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.